



October 18, 2015

CareDx CEO to Present at CMS Panel Meeting on Monday, October 19 at 8:45am ET

BRISBANE, Calif., Oct. 18, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, announced that CEO Peter Maag, PhD will present to the Advisory Panel on Clinical Diagnostic Laboratory Tests on Monday, October 19, 2015 in Baltimore, MD.

In his presentation, Mr. Maag plans to emphasize that a gapfill method is a more appropriate approach for establishing the reimbursement pricing of AlloMap, than the currently proposed crosswalk method. CareDx looks forward to working with CMS collaboratively through the open comment period.

The meeting will commence at 8:45 am Eastern Time on Monday, October 19th. To listen to the live webcast, please visit <http://www.cms.gov/live/>.

About CareDx

CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements including, but not limited to statements regarding the Company's expectations regarding future potential, development and commercial activities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward looking statements, including CareDx's limited operating history and experience with developing new markets; risk relating to new partnerships and commercialization of those relationships, as well as other risks stated in CareDx's filings with the SEC located at www.sec.gov. CareDx disclaims any obligation to publicly update or revise any forward looking statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Media Contacts

Molly Martell

Senior Director, Marketing

T: +1 415-728-6307

E: [mmartell@caredx.com](mailto:mmartell@ caredx.com)

Investor Contact

Westwicke Partners, LLC

Leigh J. Salvo Principal

T: +1 415-513-1281

E: leigh.salvo@westwicke.com



Source: CareDx, Inc.

News Provided by Acquire Media